Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Decyl-triphenylphosphonium (dTPP) is a lipophilic quaternary phosphonium cation that selectively accumulates within the mitochondrial matrix, driven by the mitochondrial membrane potential. It is widely utilized in biomedical research as a tool compound and an inactive control or reference for mitochondria-targeted therapeutics and antioxidants (such as MitoQ and SkQ1) to distinguish the effects of mitochondrial targeting from those of the active cargo. In preclinical oncology studies, dTPP has been investigated for its ability to induce mitochondrial membrane depolarization, elevate reactive oxygen species (ROS) levels, and selectively target cancer stem cells (CSCs) and chemoresistant tumor cells, particularly when combined with inhibitors of hydroperoxide metabolism or glycolysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on decyltriphenylphosphonium.